CUI1 stringlengths 8 8 | RELA stringlengths 3 54 | CUI2 stringlengths 8 8 | Name1 stringlengths 1 2.86k ⌀ | Name2 stringlengths 1 2.86k ⌀ | Def1 stringlengths 1 8.95k ⌀ | Def2 stringlengths 1 8.95k ⌀ |
|---|---|---|---|---|---|---|
C0000618 | chemotherapy_regimen_has_component | C5891081 | mercaptopurine | Cytarabine/Etoposide/Mercaptopurine/Methotrexate Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of cytarabine, etoposide, mercaptopurine, and methotrexate that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C5891089 | mercaptopurine | Dexamethasone/Mercaptopurine/Methotrexate/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of dexamethasone, mercaptopurine, methotrexate, and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | subset_includes_concept | C5910040 | mercaptopurine | HemOnc Agent Terminology | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A terminology set that includes pharmacologic agents found in the HemOnc knowledge base. |
C0000618 | chemotherapy_regimen_has_component | C5962709 | mercaptopurine | Mercaptopurine/Intrathecal Methotrexate/Oral Methotrexate Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of intrathecal methotrexate, oral methotrexate and mercaptopurine that can be used in the treatment of acute lymphoblastic leukemia (ALL). This regimen is part of the CALGB 8811 Larson regimen. |
C0000618 | chemotherapy_regimen_has_component | C5962820 | mercaptopurine | Cyclophosphamide/Cytarabine/Mercaptopurine/Intrathecal Methotrexate/Pegaspargase/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of cyclophosphamide, cytarabine, mercaptopurine, intrathecal methotrexate, pegaspargase and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C5962827 | mercaptopurine | Dexamethasone/Mercaptopurine/Intrathecal Methotrexate/Methotrexate/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of dexamethasone, mercaptopurine, intrathecal methotrexate, methotrexate and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C5963156 | mercaptopurine | Cyclophosphamide/Cytarabine/Intrathecal Hydrocortisone/Mercaptopurine/Intrathecal Methotrexate/Pegaspargase/Prednisone/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of cyclophosphamide, cytarabine, intrathecal hydrocortisone, mercaptopurine, intrathecal methotrexate, pegaspargase, prednisone, and vincristine that can be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C5963157 | mercaptopurine | Intrathecal Hydrocortisone/Mercaptopurine/Methotrexate/Prednisone/Vincristine Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of intrathecal hydrocortisone, mercaptopurine, methotrexate, prednisone, and vincristine that can be used in the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | chemotherapy_regimen_has_component | C5963326 | mercaptopurine | Cytarabine/Mercaptopurine/Methotrexate/Methylprednisolone Regimen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | A regimen consisting of cytarabine, mercaptopurine, methotrexate, and methylprednisolone that can be used for the treatment of acute lymphoblastic leukemia (ALL). |
C0000618 | has_ingredient | C0689485 | mercaptopurine | mercaptopurine 50 MG Oral Tablet | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000618 | has_ingredient | C3817479 | mercaptopurine | mercaptopurine 20 MG/ML Oral Suspension | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | null |
C0000641 | inverse_isa | C0007090 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | Carcinogens | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. |
C0000641 | inverse_isa | C0026879 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | Mutagens | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. |
C0000641 | mapped_to | C0049780 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-dihydroxy-9,10-epoxide-7,8,9,10-tetrahydrobenzo(a)pyrene-10-deoxyguanosine | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0049781 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 7,8-dihydroxy-9,10-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene-DNA adduct | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0053196 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-DNA | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0084096 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | poly(dG-dC)-benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0105612 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | benzo(a)pyrene 7,8-dihydrodiol-9,10-epoxide poly((dA-dC).(dG-dT)) adduct | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0251251 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 3-nitrobenzo(a)pyrene-7,8-diol-9,10-epoxide | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0251253 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 10-N(2)-deoxyguanosine-3-nitrobenzo(a)pyrene-7,8,9-triol | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0383030 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | N(6)-(10-(7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo(a)pyrenyl))-2'-deoxyadenosine | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0387694 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 1-nitrobenzo(a)pyrene-7,8-diol-9,10-epoxide | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0648120 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | benz(a)pyrene-7,8-dihydrodiol-9,10-epoxide poly((dT-dC).(dG-dA)) adduct | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0676758 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | glutathione-BPDE conjugate | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | mapped_to | C0963166 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | benzo(a)pyrene 7,8-diol-9,10-epoxide-N2-deoxyguanosine | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | null |
C0000641 | see_from | C0178502 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | benzopyrenediol epoxide | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | 9,10-dihydroxy-11,12-epoxy-9,10,11,12- tetranhydrobenzo(a)pyrene, a metabolite of BAPN, has been called "the ultimate carcinogen"; extremely electrophilic, it can form covalent adducts with both DNA and proteins. |
C0000641 | inverse_isa | C1511659 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | DNA Adduct Forming Agent | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | An agent capable of attaching to DNA with a covent bond. DNA adduct forming agents cause disruption of DNA replication and mitosis. |
C0000641 | subset_includes_concept | C3899741 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | CTRP Terminology | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | Terminology that is used to support NCI's Clinical Trials Reporting Program (CTRP), a database that captures the required reporting data for all NCI-sponsored clinical trials. |
C0000641 | subset_includes_concept | C4684827 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | CTRP Biomarker Terminology | 7,8,8a,9a-Tetrahydrobenzo(10,11)chryseno (3,4-b)oxirene-7,8-diol. A benzopyrene derivative with carcinogenic and mutagenic activity. | A set of terms that is comprised of the biomarkers referenced in NCI-sponsored clinical trials. |
C0000644 | mapped_to | C0755763 | 7-Alkoxycoumarin O-Dealkylase | cytochrome P-450 CYP76B1 (Helianthus tuberosus) | A drug-metabolizing enzyme found in the hepatic, placental and intestinal microsomes that metabolizes 7-alkoxycoumarin to 7-hydroxycoumarin. The enzyme is cytochrome P-450- dependent. | null |
C0000644 | mapped_to | C1723622 | 7-Alkoxycoumarin O-Dealkylase | 3-cyano-7-ethoxycoumarin-o-deethylase, Littorina littorea | A drug-metabolizing enzyme found in the hepatic, placental and intestinal microsomes that metabolizes 7-alkoxycoumarin to 7-hydroxycoumarin. The enzyme is cytochrome P-450- dependent. | null |
C0000657 | mapped_from | C0074512 | 7SL RNA | Signal Recognition Particle | null | A cytosolic ribonucleoprotein complex that acts to induce elongation arrest of nascent presecretory and membrane proteins until the ribosome becomes associated with the rough endoplasmic reticulum. It consists of a 7S RNA and at least six polypeptide subunits (relative molecular masses 9, 14, 19, 54, 68, and 72K). |
C0000657 | mapped_from | C0284778 | 7SL RNA | RNA, Small Cytoplasmic | null | Small RNAs found in the cytoplasm usually complexed with proteins in scRNPs (RIBONUCLEOPROTEINS, SMALL CYTOPLASMIC). |
C0000658 | mapped_to | C0044642 | 8,11,14-Eicosatrienoic Acid | 10,11,12-trihydroxyeicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0044676 | 8,11,14-Eicosatrienoic Acid | 10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0044709 | 8,11,14-Eicosatrienoic Acid | 11,12-dihydroxy-5,8,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0044712 | 8,11,14-Eicosatrienoic Acid | 11,12-epoxy-5,8,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0044714 | 8,11,14-Eicosatrienoic Acid | 11,14,17-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0044740 | 8,11,14-Eicosatrienoic Acid | 11-glutathionylhepoxilin A3 | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0044844 | 8,11,14-Eicosatrienoic Acid | 14,15-dihydroxy-5,8,11-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0044845 | 8,11,14-Eicosatrienoic Acid | 14,15-epoxy-5,8,11-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0044889 | 8,11,14-Eicosatrienoic Acid | 15-hydroxy-8,11,13-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0046354 | 8,11,14-Eicosatrienoic Acid | 2-methyl-8,12,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0048925 | 8,11,14-Eicosatrienoic Acid | 5,6-epoxy-8,11,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0048945 | 8,11,14-Eicosatrienoic Acid | mead acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | A polyunsaturated long-chain fatty acid with a 20-carbon backbone and 3 double bonds, originating from the 9th, 12th and 15th positions from the methyl end, with all bonds in the cis- configuration. |
C0000658 | mapped_to | C0048947 | 8,11,14-Eicosatrienoic Acid | 5,8,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0049981 | 8,11,14-Eicosatrienoic Acid | 8,11,12-trihydroxy-5,9,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0049996 | 8,11,14-Eicosatrienoic Acid | 8,9-epoxyeicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0050077 | 8,11,14-Eicosatrienoic Acid | 8-hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0058977 | 8,11,14-Eicosatrienoic Acid | eicosa-8,11,14-trien-5-ynoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0059763 | 8,11,14-Eicosatrienoic Acid | ethyl dihomo-gamma-linolenate | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0080537 | 8,11,14-Eicosatrienoic Acid | 11,14,15-trihydroxyeicosa-5,8,12-trienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0080556 | 8,11,14-Eicosatrienoic Acid | 12-hydroxy-5,8,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0080565 | 8,11,14-Eicosatrienoic Acid | 14,15-episulfide eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0165000 | 8,11,14-Eicosatrienoic Acid | 14-iodo-15-hydroxy-5,8,11-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0216944 | 8,11,14-Eicosatrienoic Acid | tridihomo-gamma-linolenoylglycerol | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0380774 | 8,11,14-Eicosatrienoic Acid | mead ethanolamide | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0532705 | 8,11,14-Eicosatrienoic Acid | 11,12-thiiranohepoxilin A3 | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0541092 | 8,11,14-Eicosatrienoic Acid | 14,15-dihydroxyeicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0608943 | 8,11,14-Eicosatrienoic Acid | methyl branched 8,11,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0616799 | 8,11,14-Eicosatrienoic Acid | 11-hydroxy-8,12,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0622262 | 8,11,14-Eicosatrienoic Acid | 5,6-dihydroxy-8,11,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0627323 | 8,11,14-Eicosatrienoic Acid | 5,12,20-trihydroxy-8,10,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0627325 | 8,11,14-Eicosatrienoic Acid | 5,12,20-trihydroxy-6,8,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0629692 | 8,11,14-Eicosatrienoic Acid | 13-hydroxy-14,15-epoxyeicosa-5,8,11-trienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0643100 | 8,11,14-Eicosatrienoic Acid | 11,12,15-trihydroxyeicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0646425 | 8,11,14-Eicosatrienoic Acid | hepoxillin A3-D | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0657668 | 8,11,14-Eicosatrienoic Acid | 11-hydroxy-8,9-epoxyeicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0657686 | 8,11,14-Eicosatrienoic Acid | 15-hydroxy-5,8,11-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0658188 | 8,11,14-Eicosatrienoic Acid | 16-hydroxyheneicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C0915270 | 8,11,14-Eicosatrienoic Acid | 11,12-dihydroxyeicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C1122183 | 8,11,14-Eicosatrienoic Acid | PBT-3 compound | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C1122268 | 8,11,14-Eicosatrienoic Acid | 8-hydroxy-11,12-cyclopropyleicosa-5,9,14-trienoic acid methyl ester | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C1122270 | 8,11,14-Eicosatrienoic Acid | 10-hydroxy-11,12-cyclopropyleicosa-5,8,14-trienoic acid methyl ester | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C1312920 | 8,11,14-Eicosatrienoic Acid | 14,14-epoxyeicosa-5-enoic methylsulfonylimide | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C1530037 | 8,11,14-Eicosatrienoic Acid | 14,15-eicosa-5-enoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C1871490 | 8,11,14-Eicosatrienoic Acid | 11,12-epoxyeicosatrienoic acid methyl ester | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C2353695 | 8,11,14-Eicosatrienoic Acid | 15-hydroxy-11,12-epoxyeicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C2744224 | 8,11,14-Eicosatrienoic Acid | 20-iodo-14,15-epoxyeicosa-5-enoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C3492426 | 8,11,14-Eicosatrienoic Acid | 20-hydroxy-11,12-epoxyeicosa-8(Z)-enoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C4507548 | 8,11,14-Eicosatrienoic Acid | 12-hydroxy-8,10,14-eicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C4705442 | 8,11,14-Eicosatrienoic Acid | 15-hydroxy-8,9-epoxyeicosatrienoic acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | mapped_to | C5227007 | 8,11,14-Eicosatrienoic Acid | EET-B | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000658 | inverse_isa | C0133860 | 8,11,14-Eicosatrienoic Acid | fatty acids, omega-6 | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | FATTY ACIDS which have the first unsaturated bond in the sixth position from the omega carbon. A typical American diet tends to contain substantially more omega-6 than OMEGA-3 FATTY ACIDS. |
C0000658 | inverse_isa | C2348388 | 8,11,14-Eicosatrienoic Acid | Eicosatrienoic Acid | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | A polyunsaturated long-chain fatty acid with a 20-carbon backbone and exactly 3 double bonds. Six different isomers can be called by this name. |
C0000658 | subset_includes_concept | C1880653 | 8,11,14-Eicosatrienoic Acid | FDA Established Names and Unique Ingredient Identifier Codes Terminology | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | The terminology that includes terms pertaining to FDA/USP Substance Registration System (SRS), which is to support health information technology initiatives by generating unique ingredient identifiers (UNIIs) for substances in drugs, biologics, foods, and devices. |
C0000658 | inverse_isa | C0032615 | 8,11,14-Eicosatrienoic Acid | Polyunsaturated Fatty Acids | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | A fatty acid containing more than one double bond (C=C). The essential fatty acids omega-3 and omega-6 are polyunsaturated fatty acids (PUFAs) that contain 2 or more cis double bonds. Dietary intake of some PUFAs may have beneficial effects on blood pressure, serum lipds, and inflammation. Some PUFAs, such as omega-3 P... |
C0000658 | inverse_isa | C0522097 | 8,11,14-Eicosatrienoic Acid | Aliphatic carboxylic acid, C14-C26 | A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. | null |
C0000661 | mapped_to | C0050063 | 8-Bromo Cyclic Adenosine Monophosphate | 8-chloro-cyclic adenosine monophosphate | A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase. | An antimetabolite and a chlorine derivative of the intracellular secondary messenger, cyclic adenosine 3,5-monophosphate (cAMP), with potential antineoplastic activity. Tocladesine appears to be converted to 8-chloro-adenosine by phosphodiesterases and subsequently phosphorylated to 8-chloro-ATP, which functions as a p... |
C0000661 | mapped_to | C0538255 | 8-Bromo Cyclic Adenosine Monophosphate | 8-bromoadenosine-3',5'-cyclic monophosphorothioate | A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase. | null |
C0000665 | associated_with | C0270622 | oxyquinoline | Toxic encephalopathy caused by hydroxyquinoline | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
C0000665 | mapped_to | C0045679 | oxyquinoline | 2-(2-hydroxy-5-n-hexylphenyl)-8-quinolinol-4-carboxylic acid | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
C0000665 | mapped_to | C0049301 | oxyquinoline | 5-methyl-8-hydroxyquinoline | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | An antiprotozoal agent that was used in combination with tibroquinol. The combination agent was withdrawn from the market because of hepatoxicity. |
C0000665 | mapped_to | C0050098 | oxyquinoline | 8-hydroxyquinoline glucoside | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
C0000665 | mapped_to | C0050100 | oxyquinoline | 8-hydroxyquinoline-5-sulfonic acid | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
C0000665 | mapped_to | C0054157 | oxyquinoline | broxyquinoline | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
C0000665 | mapped_to | C0063473 | oxyquinoline | indium oxine | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
C0000665 | mapped_to | C0063724 | oxyquinoline | brobenzoxaldine, broxyquinoline drug combination | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
C0000665 | mapped_to | C0063725 | oxyquinoline | intetrix | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
C0000665 | mapped_to | C0068576 | oxyquinoline | Nestosyl ointment | An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.